6/18/2009

The U.S. gross sale of therapies based on adult stem cells is expected to reach more than $100 million this year, and it could climb to $8.2 billion by 2018, a market analyst said. Adult stem cells are more accessible, less expensive to test and less controversial than embryonic stem cells, and they have also been studied for the past 10 to 15 years, making them "ready for prime time," an expert said. Leading companies in the field include Osiris Therapeutics, StemCells, Cytori Therapeutics and Aastrom Biosciences.

Full Story:
CNNMoney

Related Summaries